ANXA5 and urinary bladder cancer: Figure 3B shows the percentages of viable (Annexin V−/PI−), early apoptotic (Annexin V+/PI−), late apoptotic (Annexin V+/PI+), and necrotic cells (Annexin V−/PI+) after tangeretin treatment. The results demonstrated that 0, 20, 40, and 60 μM tangeretin treatment caused early apoptosis in 1.3%, 6.5%, 7.66%, and 10.5%, and late apoptosis in 1.8%, 6.3%, 7.6%, and 18% of BFTC-905 cells, respectively, indicating that tangeretin caused apoptosis in bladder cancer cells, as shown in Figure 3B.